Permira completed the acquisition of Kedrion and Bio Products Laboratory in a $2.7bn deal.

Permira, a private equity firm, completed the acquisition of Kedrion, a provider of plasma-derived therapies, and Bio Products Laboratory, a manufacturer of a wide range of products from blood plasma, in a $2.7bn deal. The merger of Kedrion and Bio Products Laboratory was also supported by investments from the Marcucci Family, Abu Dhabi Investment Authority and Ampersand Capital Partners. “We’re honoured to be partnering with the Marcucci Family on this exciting project that brings together two high-quality players – Kedrion and BPL – in the plasma-derived therapeutics space, a growing industry with an important unmet patient demand. This investment fits squarely within the Specialty Pharma segment of our strategy: backing highly specialised platforms in attractive and resilient therapeutic areas. Together, the two companies will have an exciting portfolio of pharmaceutical products aimed at helping patients with compromised immune systems or bleeding disorders and we look forward to working with the teams to build a leading rare disease specialist platform with a deep commitment to its patients and donors,” Silvia Oteri, Permira Head of Healthcare.